Evaluation of Patients with a Recent Clinical Fracture and Osteoporosis, a Multidisciplinary Approach

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2008 Aug 6

PMID 18680609

Citations 15

Authors

Bianca Dumitrescu

Svenjhalmar van Helden

Rene Ten Broeke

Arie Nieuwenhuijzen-Kruseman

Caroline Wyers

Gabriela Udrea

Sjef van der Linden

Piet Geusens

Affiliations

Soon will be listed here.

Abstract

The aetiology of osteoporotic fractures is multifactorial, but little is known about the way to evaluate patients with a recent clinical fracture for the presence of secondary osteoporosis. The purpose of this study was to determine the prevalence of contributors to secondary osteoporosis in patients presenting with a clinical vertebral or non-vertebral fracture. Identifying and correcting these contributors will enhance treatment effect aimed at reducing the risk of subsequent fractures. In a multidisciplinary approach, including evaluation of bone and fall-related risk factors, 100 consecutive women (n = 73) and men (n = 27) older than 50 years presenting with a clinical vertebral or non-vertebral fracture and having osteoporosis (T-score < or =-2.5) were further evaluated clinically and by laboratory testing for the presence of contributors to secondary osteoporosis. In 27 patients, 34 contributors were previously known, in 50 patients 52 new contributors were diagnosed (mainly vitamin D deficiency in 42) and 14 needed further exploration because of laboratory abnormalities (mainly abnormal thyroid stimulating hormone in 9). The 57 patients with contributors were older (71 vs. 64 yrs, p < 0.01), had more vertebral deformities (67% vs. 44%, p < 0.05) and a higher calculated absolute 10-year risk for major (16.5 vs. 9.9%, p < 0.01) and for hip fracture (6.9 vs. 2.4%, p < 0.01) than patients without contributors. The presence of contributors was similar between women and men and between patients with fractures associated with a low or high-energy trauma. We conclude that more than one in two patients presenting with a clinical vertebral or non-vertebral fracture and BMD-osteoporosis have secondary contributors to osteoporosis, most of which were correctable. Identifying and correcting these associated disorders will enhance treatment effect aimed at reducing the risk of subsequent fractures in patients older than 50 years.

Citing Articles

Risk Factors for Fragility Fractures in Chronic Lymphocytic Leukemia.

Petty L, Stephens D, Sharma A Cureus. 2024; 16(2):e54774.

PMID: 38523984 PMC: 10961164. DOI: 10.7759/cureus.54774.

Vitamin D Supplementation and Its Impact on Different Types of Bone Fractures.

Erdmann J, Wicinski M, Szyperski P, Gajewska S, Ohla J, Slupski M Nutrients. 2023; 15(1).

PMID: 36615761 PMC: 9824692. DOI: 10.3390/nu15010103.

The Phenotype of Patients with a Recent Fracture: A Literature Survey of the Fracture Liaison Service.

Vranken L, Wyers C, van den Bergh J, Geusens P Calcif Tissue Int. 2017; 101(3):248-258.

PMID: 28536889 PMC: 5544781. DOI: 10.1007/s00223-017-0284-1.

High prevalence of secondary factors for bone fragility in patients with a recent fracture independently of BMD.

Malgo F, Appelman-Dijkstra N, Termaat M, van der Heide H, Schipper I, Rabelink T Arch Osteoporos. 2016; 11:12.

PMID: 26906974 PMC: 4764633. DOI: 10.1007/s11657-016-0258-3.

Gilasi H, Soori H, Yazdani S, Taheri Tenjani P Arch Trauma Res. 2015; 4(1):e22925.

PMID: 26064869 PMC: 4460262. DOI: 10.5812/atr.22925.

References

. Prevention and management of osteoporosis. World Health Organ Tech Rep Ser. 2004; 921:1-164, back cover. View

Heaney R, Davies K, Chen T, Holick M, Barger-Lux M . Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2002; 77(1):204-10. DOI: 10.1093/ajcn/77.1.204. View

Vestergaard P, Rejnmark L, Mosekilde L . Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. Calcif Tissue Int. 2005; 77(3):139-44. DOI: 10.1007/s00223-005-0068-x. View

Wagman R, Marcus R . Beyond bone mineral density-navigating the laboratory assessment of patients with osteoporosis. J Clin Endocrinol Metab. 2002; 87(10):4429-30. DOI: 10.1210/jc.2002-021310. View

Feldstein A, Nichols G, Elmer P, Smith D, Aickin M, Herson M . Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am. 2003; 85(12):2294-302. View

. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference. South Med J. 2001; 94(6):569-73. View

van Helden S, van Geel A, Geusens P, Kessels A, Nieuwenhuijzen Kruseman A, Brink P . Bone and fall-related fracture risks in women and men with a recent clinical fracture. J Bone Joint Surg Am. 2008; 90(2):241-8. DOI: 10.2106/JBJS.G.00150. View

Nieschlag E, Swerdloff R, Behre H, Gooren L, Kaufman J, Legros J . Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl. 2005; 28(3):125-7. DOI: 10.1111/j.1365-2605.2005.00553.x. View

Boonen S, Vanderschueren D, Haentjens P, Lips P . Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update. J Intern Med. 2006; 259(6):539-52. DOI: 10.1111/j.1365-2796.2006.01655.x. View

10.

Boonen S, Bischoff-Ferrari H, Cooper C, Lips P, Ljunggren O, Meunier P . Addressing the musculoskeletal components of fracture risk with calcium and vitamin D: a review of the evidence. Calcif Tissue Int. 2006; 78(5):257-70. DOI: 10.1007/s00223-005-0009-8. View

11.

Bischoff H, Stahelin H, Dick W, Akos R, Knecht M, Salis C . Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003; 18(2):343-51. DOI: 10.1359/jbmr.2003.18.2.343. View

12.

Heaney R . The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005; 97(1-2):13-9. DOI: 10.1016/j.jsbmb.2005.06.020. View

13.

Geusens P, Lems W, Verhaar H, Leusink G, Goemaere S, Zmierczack H . Review and evaluation of the Dutch guidelines for osteoporosis. J Eval Clin Pract. 2006; 12(5):539-48. DOI: 10.1111/j.1365-2753.2006.00647.x. View

14.

. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994; 843:1-129. View

15.

Chevalley T, Hoffmeyer P, Bonjour J, Rizzoli R . An osteoporosis clinical pathway for the medical management of patients with low-trauma fracture. Osteoporos Int. 2002; 13(6):450-5. DOI: 10.1007/s001980200053. View

16.

Kanis J, Burlet N, Cooper C, Delmas P, Reginster J, Borgstrom F . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008; 19(4):399-428. PMC: 2613968. DOI: 10.1007/s00198-008-0560-z. View

17.

Liebman S, Taylor J, Bushinsky D . Idiopathic hypercalciuria. Curr Rheumatol Rep. 2006; 8(1):70-5. DOI: 10.1007/s11926-006-0029-z. View

18.

Deutschmann H, Weger M, Weger W, Kotanko P, Deutschmann M, Skrabal F . Search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density. J Intern Med. 2003; 252(5):389-97. DOI: 10.1046/j.1365-2796.2002.01040.x. View

19.

Nieschlag E, Swerdloff R, Behre H, Gooren L, Kaufman J, Legros J . Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. J Androl. 2006; 27(2):135-7. DOI: 10.2164/jandrol.05047. View

20.

Geusens P . Review of guidelines for testing and treatment of osteoporosis. Curr Osteoporos Rep. 2005; 1(2):59-65. DOI: 10.1007/s11914-003-0010-y. View